Given the clinical evidence reviewed above, patients with type 2 diabetes and/or obesity are the most promising candidate population to benefit from GLP-1RA-centered pharmacotherapy to improve cardiovascular and kidney outcomes
If in doubt, ask your doctor, pharmacist, or diabetes nurse again if you have any questions
Originally developed to help with blood sugar regulation, these medications are now being used to support weight loss, enhance metabolic health, and treat diabetes, inflammation, and other health conditions
Theyre becoming tools to solve one of our hardest challenges: how to treat serious mental illness without sacrificing physical health
That means the risk of acquiring contact sensitivty is quite low
GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis